A Clinical Trial to Evaluate the Safety and Effectiveness of the Collagen-phosphorylcholine Corneal Substitutes in Patients Requiring Lamellar Keratoplasty
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Corneal Ulcer
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Incidence of Treatment-Emergent Adverse Events
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
In this study the safety and effectiveness of biosynthetic cornea, comprising interpenetrating networks of recombinant human collagen and phosphorylcholine, will be tested in patients with severe corneal pathology (corneal ulcers or corneal opacification from corneal injury, burn or infection) - diseases, where human donor cornea transplantation (the only widely accepted treatment) carries a high risk of rejection.
Detailed Description
Collagen-phosphorylcholine corneal substitute will be implanted in patient's corneas with severe pathology (corneal ulcer, corneal leukoma after burn, trauma or infection) using anterior lamellar keratoplasty technique, i.e. when patient's diseased cornea is removed it will be substituted with proposed transparent implant. Usually these patients are grafted with human donor cornea, but the latter frequently fails due to graft-versus-host problems. We will test the safety (incidence of adverse events, biocompatability) and the effectiveness (ability to promote healing and increase vision) of developed biosynthetic corneas in 10 patients with corneal pathology, where human donor cornea carries a high risk of rejection. The patients will be follow-uped for 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must sign and be given a copy of the written Informed Consent form.
- •Subjects with best corrected distance visual acuity 20/200 or worse as a result of corneal ulcer or corneal scar due to burn, injury or infection in the operative eye.
- •Subjects must be willing and able to return for scheduled follow-up examinations for 12 months after surgery.
Exclusion Criteria
- •Subjects with severe or life-threatening systemic disease.
- •Subjects with uncontrolled hypertension.
- •Subjects with uncontrolled diabetes or insulin-dependent diabetes.
- •Subjects with glaucoma in either eye.
- •Subjects with marked microphthalmos or aniridia in either eye.
- •Subjects with any other serious ocular pathology, serious ocular complications at the time of corneal transplant underlying serious medical conditions, based on the investigator's medical judgment.
- •Subjects which are or lactating or who plan to become pregnant over the course of the clinical investigation.
Outcomes
Primary Outcomes
Incidence of Treatment-Emergent Adverse Events
Time Frame: 12 months
Implant safety and tolerability will be measured by absence/presence of its lysis as well as by degree of eye inflammation based on conjunctival injection, perifocal corneal haze, aqueous humor transparency, increased intraocular pressure and self reported postoperative pain. Each item is scored 0-4: 0 = no symptom, 4 = severe symptom.
Secondary Outcomes
- Number of Participants With Healed Cornea at 12 Months(12 months)
- Number of Participants With Improved Visual Acuity at 12 Months(12 months)